Advancing to Third-Line Therapy: Belumosudil in cGVHD
Panelists discuss how belumosudil serves as a third-line therapy option for patients with chronic graft-versus-host disease (cGVHD), exploring its role in advancing treatment when earlier options have been exhausted.
EP: 1.Chronic GVHD and Patient Quality of Life: Multisystem Effects and Functional Impairments
EP: 2.Multisystem cGVHD Manifestations: A Case Study with NIH Organ-Specific Scoring
EP: 3.Stratifying cGVHD Severity and Tailoring Therapy: Systemic Treatments and Supportive Care
EP: 4.Second-Line Strategies in cGVHD: Efficacy Data with Ruxolitinib
EP: 5.Navigating the Safety Profile of Ruxolitinib in cGVHD
EP: 6.Advancing to Third-Line Therapy: Belumosudil in cGVHD
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
